Alright, let's delve deep into the world of figures and facts to discover the nitty-gritty of Autolus Therapeutics plc's third-quarter balance sheet for the fiscal year 2023. First of all, hats off to your discerning eye for being a savvy investor willing to swim through the sea of financial statements!

The company had total assets of $406,098,000, comprised mainly of current assets amounting to $308,382,000 and noncurrent assets of $97,716,000. A trove of wealth here is the 'other current assets' valued at a considerable $300,847,000, something to note for sure.

On the other side of the balance sheet, total liabilities come in at $225,580,000. A relatively low figure of $37,540,000 for current liabilities strikes a positive note. However, there is a substantial sum tied in noncurrent liabilities, a rather gloomy $188,040,000.

The equity section attracts attention as well, with a total equity of $180,518,000, wholly attributable to the parent. Noteworthy is the absence of equity related to noncontrolling interest, clearly painting a picture of stable ownership structure. Digging a little deeper, a negative comprehensive income of $51,686,000 is revealed, reflecting a financial hiccup for the period in question.

Moving on to the deciphering of income statement figures, the report card exhibits a net income loss of $45,849,000. The loss is primarily driven by substantial operating income losses amounting to $47,824,000. This casts a not-so-rosy picture, decrypting which reveals that the company has been focusing largely on research and development to the tune of $37,237,000.

Our homestretch of analysis reveals the diluted and basic earnings per share, both standing at a loss of $0.26. This reinforces the evidence of the company facing a challenging period. The losses, primarily due to operating inefficiencies and sizeable R&D expense, might provide greater value in the long term, a promising avenue for future profits.

So, that's the roundup of Autolus Therapeutics plc's financials. With a substantial asset base, sizable equity, and a slight hitch of considerable losses currently driven by ramp-up of R&D, it commands a close watch for future prospects. Remember, every cloud has a silver lining; in this case, it's the potential yields of their R&D investments. Now, isn't that a thrilling rollercoaster ride of numbers?